These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15583693)

  • 21. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognize common determinants on non-ovarian tumour clones.
    Ioannides CG; Fisk B; Pollack MS; Frazier ML; Taylor Wharton J; Freedman RS
    Scand J Immunol; 1993 Apr; 37(4):413-24. PubMed ID: 8469924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes.
    Nguyen T; Naziruddin B; Dintzis S; Doherty GM; Mohanakumar T
    Int J Cancer; 1999 May; 81(4):607-15. PubMed ID: 10225452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene.
    Ioannides CG; Fisk B; Fan D; Biddison WE; Wharton JT; O'Brian CA
    Cell Immunol; 1993 Oct; 151(1):225-34. PubMed ID: 7691418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
    Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ
    Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
    Disis ML; Smith JW; Murphy AE; Chen W; Cheever MA
    Cancer Res; 1994 Feb; 54(4):1071-6. PubMed ID: 7508819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI.
    Mamalaki A; Gritzapis AD; Kretsovali A; Belimezi M; Papamatheakis J; Perez SA; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2003 Aug; 52(8):513-22. PubMed ID: 12715240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression.
    Kono K; Halapi E; Hising C; Petersson M; Gerdin E; Vanky F; Kiessling R
    Int J Cancer; 1997 Jan; 70(1):112-9. PubMed ID: 8985099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties.
    Gritzapis AD; Fridman A; Perez SA; La Monica N; Papamichail M; Aurisicchio L; Baxevanis CN
    Vaccine; 2009 Dec; 28(1):162-70. PubMed ID: 19799847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells.
    Kaplan BL; Norell H; Callender GG; Ohlum T; Kiessling R; Nishimura MI
    Cancer Immunol Immunother; 2006 Jun; 55(6):653-62. PubMed ID: 16151808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues.
    Vertuani S; Sette A; Sidney J; Southwood S; Fikes J; Keogh E; Lindencrona JA; Ishioka G; Levitskaya J; Kiessling R
    J Immunol; 2004 Mar; 172(6):3501-8. PubMed ID: 15004150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer.
    Yu Y; Pilgrim P; Zhou W; Gagliano N; Frezza EE; Jenkins M; Weidanz JA; Lustgarten J; Cannon M; Bumm K; Cobos E; Kast WM; Chiriva-Internati M
    Viral Immunol; 2008 Dec; 21(4):435-42. PubMed ID: 19115932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro.
    Li G; Zeng Y; Chen X; Larmonier N; Sepassi M; Graner MW; Andreansky S; Brewer MA; Katsanis E
    Clin Exp Immunol; 2007 Apr; 148(1):136-45. PubMed ID: 17349014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumours.
    Sotiropoulou PA; Perez SA; Iliopoulou EG; Missitzis I; Voelter V; Echner H; Baxevanis CN; Papamichail M
    Br J Cancer; 2003 Sep; 89(6):1055-61. PubMed ID: 12966425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Redirecting effector T cells through their IL-2 receptors.
    Lustgarten J; Marks J; Sherman LA
    J Immunol; 1999 Jan; 162(1):359-65. PubMed ID: 9886407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells.
    Ramakrishna V; Ross MM; Petersson M; Gatlin CC; Lyons CE; Miller CL; Myers HE; McDaniel M; Karns LR; Kiessling R; Parmiani G; Flyer DC
    Int Immunol; 2003 Jun; 15(6):751-63. PubMed ID: 12750359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
    Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
    Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity.
    Lustgarten J; Dominguez AL; Cuadros C
    Eur J Immunol; 2004 Mar; 34(3):752-761. PubMed ID: 14991605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Shared T cell epitopes in epithelial tumors.
    Peoples GE; Smith RC; Linehan DC; Yoshino I; Goedegebuure PS; Eberlein TJ
    Cell Immunol; 1995 Sep; 164(2):279-86. PubMed ID: 7656335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.